 Following discussions with the FDA, Applied Therapeutics Inc NASDAQ: APLT has decided to hold on submitting a marketing application for AT-007 for Galactosemia pending additional talks with the agency. Although the Galactosemia program had previously been discussed for Accelerated Approval based on reduction in galactitol, the FDA has now indicated that clinical outcomes data will likely be required for approval. 